Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Giovanni Santostasi, Gentian Denas & Vittorio Pengo. (2023) New pharmacotherapeutic options for oral anticoagulant treatment in atrial fibrillation patients aged 65 and older: factor XIa inhibitors and beyond. Expert Opinion on Pharmacotherapy 24:12, pages 1335-1347.
Read now
Read now
Rishi Chandiramani, Alessandro Spirito, James W. Johnson, Adhya Mehta, Birgit Vogel, Robert T. Faillace & Roxana Mehran. (2023) Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. Expert Review of Cardiovascular Therapy 21:5, pages 311-328.
Read now
Read now
Brandon Havranek & Shahidul M. Islam. (2021) An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease. Journal of Biomolecular Structure and Dynamics 39:12, pages 4304-4315.
Read now
Read now
Rami A. Al-Horani. (2020) Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opinion on Therapeutic Patents 30:1, pages 39-55.
Read now
Read now
Antonio Gómez-Outes, Minerva García-Fuentes & Mª Luisa Suárez-Gea. (2017) Discovery methods of coagulation-inhibiting drugs. Expert Opinion on Drug Discovery 12:12, pages 1195-1205.
Read now
Read now
Articles from other publishers (45)
Jiangming Wang, Xiaojing Sun, Na Li, Ruilong Sheng & Ruihua Guo. (2023) An Overview of Thrombin Inhibitors in the Perspective of Structureactivity
Relationships. Current Medicinal Chemistry 30:25, pages 2864-2930.
Crossref
Crossref
Yunqing Xia, Yu Hu & Liang Tang. (2023) Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances. Pharmaceuticals 16:6, pages 866.
Crossref
Crossref
Zhouling Xie, Zhiwei Meng, Xiaoxiao Yang, Yajun Duan, Qin Wang & Chenzhong Liao. (2023) Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives. Journal of Medicinal Chemistry 66:8, pages 5332-5363.
Crossref
Crossref
Xinkang Wang, Qiu Li, Fuyong Du, Neetu Shukla, Andrea R. Nawrocki & Madhu Chintala. (2023) Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. TH Open 07:02, pages e97-e104.
Crossref
Crossref
Wu YangJames R. CorteJoseph M. Luettgen. 2022. 2022 Medicinal Chemistry Reviews. 2022 Medicinal Chemistry Reviews
117
141
.
Juan J. Badimon, Gines Escolar & M. Urooj Zafar. (2022) Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of Cardiovascular Development and Disease 9:12, pages 437.
Crossref
Crossref
Awital Bar Barroeta, J. Arnoud Marquart, Kamran Bakhtiari, Alexander B. Meijer, Rolf T. Urbanus & Joost C.M. Meijers. (2022) Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen. Journal of Thrombosis and Haemostasis 20:11, pages 2538-2549.
Crossref
Crossref
Tingting Li, Jiang Liu & Weihua Wu. (2022) Factor XI, a potential target for anticoagulation therapy for venous thromboembolism. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Ying X. GueDiana A. Gorog & Gregory Y.H. Lip. (2022) Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?. Circulation 146:16, pages 1207-1209.
Crossref
Crossref
Carolina E. Touw, Banne Nemeth, Araci M. R. Rondon, Raymond A. van Adrichem, Ton Lisman, Henri H. Versteeg, Inger B. Schipper, Rob G. H. H. Nelissen, Mettine H. A. Bos & Suzanne C. Cannegieter. (2022) Lower-leg injury and knee arthroscopy have distinct effects on coagulation. Blood Advances 6:17, pages 5232-5243.
Crossref
Crossref
Guozhang Xu, Zhijie Liu, Xinkang Wang, Tianbao Lu, Renee L. DesJarlais, Tho Thieu, Jing Zhang, Zheng Huang Devine, Fuyong Du, Qiu Li, Cynthia M. Milligan, Paul Shaffer, Peder E. Cedervall, John C. Spurlino, Christopher F. Stratton, Beth Pietrak, Lawrence M. Szewczuk, Victoria Wong, Ruth A. Steele, Wouter Bruinzeel, Madhu Chintala, Jose Silva, Michael D. Gaul, Mark J. Macielag & Ravi Nargund. (2022) Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions. Journal of Medicinal Chemistry 65:15, pages 10419-10440.
Crossref
Crossref
Lucas Van Hoof, Isabelle Truyers, Hadewych Van Hauwermeiren, Bram Nachtergaele, Tom Langenaeken, Marc Jacquemin, Filip Rega, Peter Verhamme & Bart Meuris. (2022) Apixaban in a porcine model of mechanical valve thrombosis in pulmonary position—a pilot study. Interactive CardioVascular and Thoracic Surgery 35:2.
Crossref
Crossref
Awital Bar Barroeta, J. Arnoud Marquart & Joost C.M. Meijers. (2022) A FRET-based assay for the quantitation of the thrombin-factor XI interaction. Thrombosis Research 214, pages 23-28.
Crossref
Crossref
Farak Ali, Shahnaz Alom, Anshul Shakya, Surajit K. Ghosh, Udaya P. Singh & Hans R. Bhat. (2022) Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2. Archiv der Pharmazie 355:5.
Crossref
Crossref
Srabani Kar, Page Bankston, Daniel K. Afosah & Rami A. Al-Horani. (2021) Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa. Pharmaceuticals 14:9, pages 886.
Crossref
Crossref
Yu Lei, Bing Zhang, Yan Zhang, Xiwen Dai, Yulin Duan, Qing Mao, Jun Gao, Yuwei Yang, Ziyang Bao, Xuefeng Fu, Kunqi Ping, Chengda Yan, Yanhua Mou & Shaojie Wang. (2021) Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. European Journal of Medicinal Chemistry 220, pages 113437.
Crossref
Crossref
Morgan Ashcraft, Megan Douglass, YuJie Chen & Hitesh Handa. (2021) Combination strategies for antithrombotic biomaterials: an emerging trend towards hemocompatibility. Biomaterials Science 9:7, pages 2413-2423.
Crossref
Crossref
Mahita Razanakolona, Frédéric Adam, Elsa Bianchini, François Saller, Allan de Carvalho, Jean-Luc Diehl, Cécile V. Denis, Ferhat Meziani, Delphine Borgel, Julie Helms & Marc Vasse. (2021) Anti-inflammatory Activity of the Protein Z-Dependent Protease Inhibitor. TH Open 05:02, pages e220-e229.
Crossref
Crossref
Ronghua Yin, Lutan Zhou, Na Gao, Lisha Lin, Huifang Sun, Dingyuan Chen, Ying Cai, Zhili Zuo, Kaifeng Hu, Shengxiong Huang, Jikai Liu & Jinhua Zhao. (2021) Unveiling the Disaccharide-Branched Glycosaminoglycan and Anticoagulant Potential of Its Derivatives. Biomacromolecules 22:3, pages 1244-1255.
Crossref
Crossref
Yideng Liang, Joseph W. Jackson, Samuel A. Woodle, Stepan S. Surov, Leonid A. Parunov, Dorothy E. Scott, Mark Weinstein, Timothy K. Lee & Mikhail V. Ovanesov. (2021) Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays. Research and Practice in Thrombosis and Haemostasis 5:1, pages 211-222.
Crossref
Crossref
Anny Camelo‐Castillo, Francisco Marín & Vanessa Roldán. (2020) Factor XI, much more than an innocent observer. Journal of Thrombosis and Haemostasis 18:12, pages 3172-3173.
Crossref
Crossref
Rio S. Boothello, Nehru Viji Sankaranarayanan, Daniel K. Afosah, Rajesh Karuturi, Rami A. Al-Horani & Umesh R. Desai. (2020) Studies on fragment-based design of allosteric inhibitors of human factor XIa. Bioorganic & Medicinal Chemistry 28:23, pages 115762.
Crossref
Crossref
Marvin Korff, Lukas Imberg, Jonas M. Will, Nico Bückreiß, Svetlana A. Kalinina, Benjamin M. Wenzel, Gregor A. Kastner, Constantin G. Daniliuc, Maximilian Barth, Ruzanna A. Ovsepyan, Kirill R. Butov, Hans-Ulrich Humpf, Matthias Lehr, Mikhail A. Panteleev, Antti Poso, Uwe Karst, Torsten Steinmetzer, Gerd Bendas & Dmitrii V. Kalinin. (2020)
Acylated 1
H
-1,2,4-Triazol-5-amines Targeting Human Coagulation Factor XIIa and Thrombin: Conventional and Microscale Synthesis, Anticoagulant Properties, and Mechanism of Action
. Journal of Medicinal Chemistry 63:21, pages 13159-13186.
Crossref
Crossref
Srabani Kar, Madhusoodanan Mottamal & Rami A. Al‐Horani. (2020) Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia. ChemistryOpen 9:11, pages 1161-1172.
Crossref
Crossref
Edwige Lorthiois, James Roache, David Barnes-Seeman, Eva Altmann, Ulrich Hassiepen, Gordon Turner, Rohit Duvadie, Viktor Hornak, Rajeshri G. Karki, Nikolaus Schiering, Wilhelm A. Weihofen, Francesca Perruccio, Amy Calhoun, Tanzina Fazal, Darija Dedic, Corinne Durand, Solene Dussauge, Kamal Fettis, Fabien Tritsch, Celine Dentel, Adelaide Druet, Donglei Liu, Louise Kirman, Julie Lachal, Kenji Namoto, Douglas Bevan, Rose Mo, Gabriela Monnet, Lionel Muller, Richard Zessis, Xueming Huang, Loren Lindsley, Treeve Currie, Yu-Hsin Chiu, Cary Fridrich, Peter Delgado, Shuangxi Wang, Micah Hollis-Symynkywicz, Joerg Berghausen, Eric Williams, Hong Liu, Guiqing Liang, Hyungchul Kim, Peter Hoffmann, Andreas Hein, Paul Ramage, Allan D’Arcy, Stefanie Harlfinger, Martin Renatus, Simon Ruedisser, David Feldman, Jason Elliott, Richard Sedrani, Juergen Maibaum & Christopher M. Adams. (2020) Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. Journal of Medicinal Chemistry 63:15, pages 8088-8113.
Crossref
Crossref
Zahid Hussain, Andrew J. Cooke, Santhosh Neelamkavil, Lindsay Brown, Emma Carswell, Wayne M. Geissler, Zhuyan Guo, Brian Hawes, Terri M. Kelly, Yasuko Kiyoi, KehDih Lai, Charles Lesburg, Eleanor Pow, Yi Zang, Harold B. Wood, Scott D. Edmondson & Weiguo Liu. (2020) Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants. Bioorganic & Medicinal Chemistry Letters 30:16, pages 127072.
Crossref
Crossref
Daniel K. Afosah & Rami A. Al-Horani. (2020) Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies. Current Medicinal Chemistry 27:21, pages 3412-3447.
Crossref
Crossref
Mohanram Sivaraja, Daniel M. Clemens, Sivan Sizikov, Subhadra Dash, Chengpei Xu, Matthew Rienzo, Bo Yang, Molly Ryan, Madhuri Chattopadhyay, Lev Igoudin, Stephanie S. Chang, Samuel Keutzer, Piotr Zalicki, M. Angels Estiarte, Timothy P. Shiau, Kevin M. Short, David C. Williams, Anirban Datta, Nicola Pozzi, Enrico Di Cera, C. Michael Gibson, Keith A.A. Fox & David B. Kita. (2020) VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. Thrombosis Research 190, pages 112-121.
Crossref
Crossref
Dattatraya D. Gaikwad, Umakant D. Pawar, Sadhana L. Chavan, Chandrakant D. Pawar, Dattatraya N. Pansare, Rohini N. Shelke, Santosh L. Chavan & Ashok M. Zine. (2020)
Synthesis and anti‐proliferative activity studies of 2‐(2‐(trifluoromethyl)‐6‐(substituted)imidazo[1,2‐
b
]pyridazin‐3‐yl)‐
N
‐(substituted)acetamide derivatives
. Journal of Heterocyclic Chemistry 57:4, pages 1925-1935.
Crossref
Crossref
N. A. Podoplelova, V. B. Sulimov, I. S. Ilin, A. S. Tashilova, M. A. Panteleev, I. V. Ledeneva & Kh. S. Shikhaliev. (2020) Blood coagulation in the 21st century: existing knowledge, current strategies for treatment and perspective. Pediatric Hematology/Oncology and Immunopathology 19:1, pages 139-157.
Crossref
Crossref
Rami A Al-Horani. (2020) Targeting factor XI(a) for anticoagulation therapy: a patent landscape. Pharmaceutical Patent Analyst 9:1, pages 3-5.
Crossref
Crossref
Lisha Lin, Longyan Zhao, Na Gao, Ronghua Yin, Sujuan Li, Huifang Sun, Lutan Zhou, Guiling Zhao, Steven W. Purcell & Jinhua Zhao. (2020) From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors. Blood Reviews 39, pages 100615.
Crossref
Crossref
Rami A. Al‐Horani, Elsamani I. Abdelfadiel, Daniel K. Afosah, Shravan Morla, Jyothi C. Sistla, Bassem Mohammed, Erika J. Martin, Masahiro Sakagami, Donald F. Brophy & Umesh R. Desai. (2019) A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. Journal of Thrombosis and Haemostasis 17:12, pages 2110-2122.
Crossref
Crossref
Michael T. Davenport, Jordan A. Dickson, Matthew R. Johnson & Stephen Chamberland. (2019) Total Synthesis of Clavatadine B. Journal of Natural Products 82:11, pages 3191-3195.
Crossref
Crossref
Christina U. Lorentz, Norah G. Verbout, Michael Wallisch, Matthew W. Hagen, Joseph J. Shatzel, Sven R. Olson, Cristina Puy, Monica T. Hinds, Owen J.T. McCarty, David GailaniAndrás Gruber & Erik I. Tucker. (2019) Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arteriosclerosis, Thrombosis, and Vascular Biology 39:4, pages 799-809.
Crossref
Crossref
A. S. Kabankin, E. I. Sinauridze, E. N. Lipets & F. I. Ataullakhanov. (2019) Computer Design of Low-Molecular-Weight Inhibitors of Coagulation Factors. Biochemistry (Moscow) 84:2, pages 119-136.
Crossref
Crossref
Christian Ovesen, Jan Purrucker, Christian Gluud, Janus Christian Jakobsen, Hanne Christensen & Thorsten Steiner. (2018) Prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients associated with oral anticoagulant administration: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Systematic Reviews 7:1.
Crossref
Crossref
B.M. Mohammed, Q. Cheng, A. Matafonov, D.M. Monroe, J.C.M. Meijers & D. Gailani. (2018) Factor XI promotes hemostasis in factor IX‐deficient mice. Journal of Thrombosis and Haemostasis 16:10, pages 2044-2049.
Crossref
Crossref
Mimi L. Quan, Donald J. P. Pinto, Joanne M. Smallheer, William R. Ewing, Karen A. Rossi, Joseph M. Luettgen, Dietmar A. Seiffert & Ruth R. Wexler. (2018) Factor XIa Inhibitors as New Anticoagulants. Journal of Medicinal Chemistry 61:17, pages 7425-7447.
Crossref
Crossref
Rami A. Al-Horani & Daniel K. Afosah. (2018) Recent advances in the discovery and development of factor XI/XIa inhibitors. Medicinal Research Reviews 38:6, pages 1974-2023.
Crossref
Crossref
Qunchao Wei, Zhichao Zheng, Shijun Zhang, Xuemin Zheng, Fancui Meng, Jing Yuan, Yongnan Xu & Changjiang Huang. (2018) Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors. Molecules 23:8, pages 2002.
Crossref
Crossref
Peter M. Fischer. (2017) Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs. Journal of Medicinal Chemistry 61:9, pages 3799-3822.
Crossref
Crossref
Vidya Perera, Joseph M. Luettgen, Zhaoqing Wang, Charles E. Frost, Cynthia Yones, Cesare Russo, John Lee, Yue Zhao, Frank P. LaCreta, Xuewen Ma, Robert M. Knabb, Dietmar Seiffert, Mary DeSouza, Pierre Mugnier, Brenda Cirincione, Takayo Ueno & Robert J. A. Frost. (2018) First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects. British Journal of Clinical Pharmacology 84:5, pages 876-887.
Crossref
Crossref
Azeemullah A. Syed & Alka Mehta. (2018) Target Specific Anticoagulant Peptides: A Review. International Journal of Peptide Research and Therapeutics 24:1, pages 1-12.
Crossref
Crossref
Rami A. Al-Horani, Rajesh Karuturi, Michael Lee, Daniel K. Afosah & Umesh R. Desai. (2016) Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile. PLOS ONE 11:7, pages e0160189.
Crossref
Crossref